Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMA-638 · 3 trials · 2 indications
The PEFR is a participant's maximum speed of expiration, as measured with a peak flow meter. All participants were issued with the peak flow meter and instructed to perform the activity in triplicate in the morning prior to taking bronchodilator. The best among the 3 readings was selected.
The PEFR is a participant's maximum speed of expiration, as measured with a peak flow meter. All participants were issued with the peak flow meter and instructed to perform the activity in triplicate in the morning prior to taking bronchodilator. The best among the 3 readings was selected.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| IMA-638 | BIOLOGICAL | SC Injection, 12 weeks |
| placebo | OTHER | placebo |
Inclusion Criteria: * Generally healthy men and women with persistent asthma, 18 to 70 years of age, with body weight between 50 kg and 115 kg. * History of treatment with a medium to high dose of inhaled corticosteroids (ICS), with or without long-acting beta-agonists (LABA), for at least 2 months...
IMA-638 is an investigational small molecule being studied for the treatment of asthma. It has been evaluated in clinical trials for persistent asthma and in healthy volunteers. The drug is being developed by Pfizer, Inc. and is currently in Phase 2 clinical development.
IMA-638 is being developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule being studied for the treatment of asthma.
IMA-638 is in Phase 2 clinical development for asthma. It has completed Phase 1 and Phase 2 trials, including a Phase 2 study in subjects with persistent asthma. The drug is investigational and has not been approved by regulatory authorities.
IMA-638 has been studied in three completed clinical trials. These include NCT00339872, a Phase 1 study in asthma; NCT00340327, a Phase 1 study in healthy Japanese volunteers; and NCT00425061, a Phase 2 study in subjects with persistent asthma. All trials are completed.
IMA-638 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for asthma. The drug has completed clinical trials but has not received regulatory approval for any indication.